Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 15Tumor-Agnostic 2Other 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Medroxyprogesterone Acetate × Breast × Clear all
NCT00577122 2023-10-16

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Indiana University

Phase 2 Completed
30 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡